Pathobiology and Treatment of Pulmonary Hypertension in HIV Disease

摘要: Among HIV-infected people, the primary pulmonary complications among adults remain infectious. However, for those persons who receive highly active antiviral therapy, spectrum of disease is changing as a decrease in incidence opportunistic infections lung yields an increase noninfectious complications. HIV-associated arterial hypertension (HIV-PAH) these The prevalence HIV-PAH (determined different cohorts) approximately 0.5%. has dramatically changed during last ten years, which stark contrast to another complication HIV infection, Pneumocystis pneumonia, total number cases declined fivefold between 1995 and 2003. stable leads three key observations. First, PAH infected patients much greater than that IPAH general population (6–12-fold greater). Second, because 40 million people world are estimated be with individuals surviving longer, identified certain increase. Finally, observation essentially unchanged spite reduced viral load suggests pathogenesis only partly dependent on degree viremia. clinical implication observations current investigative therapies used should significantly reduce symptoms improve quality life HIV-PAH. major limiting factor use any PAH-modulating medication complicated pharmacokinetics related concurrent antiretroviral higher hepatic impairment patients. Despite limitations, it seems reasonable that, case other types PAH, early intervention potential delaying progression.